

**TABLE 169: ANEMIA TREATMENT-EXPERIENCED WITH EMERGING TREATMENTS: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL**

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF12 + LDV12	PR48	0.03 (0.00 to 0.11)	-17.95 (-20.76 to -15.29)
SOF12 + LDV12 + RBV12		0.32 (0.16 to 0.59)	-12.61 (-16.48 to -7.31)
SOF24 + LDV24 + RBV24		0.52 (0.22 to 1.05)	-8.93 (-15.10 to 0.94)
T12 PR48 q8		1.94 (1.29 to 2.78)	17.36 (5.63 to 31.61)
SIM12 PR24-48 RGT		0.83 (0.45 to 1.46)	-3.07 (-10.56 to 8.31)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SIM12 PR48		0.67 (0.38 to 1.16)	-6.07 (-12.00 to 2.77)
B32 PR36-48 RGT		2.42 (1.54 to 3.52)	26.38 (10.28 to 45.02)
SOF12 + RBV12		0.72 (0.30 to 1.59)	-5.19 (-13.33 to 10.77)
SOF24 + RBV24		0.39 (0.08 to 1.35)	-11.34 (-17.84 to 6.31)
PAR/RIT12 + OMB12 + DAS12		0.01 (0.00 to 0.07)	-18.25 (-20.96 to -15.66)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.27 (0.11 to 0.65)	-13.40 (-17.57 to -6.18)
DCV24 + ASU24 + PR24		0.27 (0.10 to 0.77)	-13.44 (-17.90 to -4.22)
SOF12 + PR12		1.02 (0.56 to 1.73)	0.28 (-8.44 to 13.04)
GRZ12 + ELB12 + RBV12		0.50 (0.17 to 1.18)	-9.31 (-15.99 to 3.36)
GRZ12 + ELB12 (50 mg q.d.)		0.04 (0.00 to 0.43)	-17.42 (-20.54 to -10.30)
GRZ18 + ELB18 (50 mg q.d.)		0.05 (0.00 to 0.45)	-17.33 (-20.52 to -9.80)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.33 (0.05 to 1.20)	-12.33 (-18.66 to 3.57)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.67 (0.20 to 1.71)	-6.07 (-15.31 to 12.90)
SOF12 + LDV12 + RBV12	SOF12 + LDV12	12.77 (2.90 to 86.65)	5.33 (2.32 to 10.02)
SOF24 + LDV24 + RBV24		21.05 (3.97 to 157.90)	8.98 (3.41 to 18.67)
T12 PR48 q8		77.44 (16.43 to 532.60)	35.28 (23.80 to 49.45)
SIM12 PR24-48 RGT		33.38 (6.74 to 260.90)	14.88 (7.58 to 26.38)
SIM12 PR48		27.31 (5.58 to 195.70)	11.82 (6.52 to 20.45)
B32 PR36-48 RGT		97.92 (21.65 to 653.60)	44.40 (28.66 to 62.71)
SOF12 + RBV12		29.46 (5.63 to 213.00)	12.71 (4.99 to 28.54)
SOF24 + RBV24		15.62 (2.11 to 144.50)	6.55 (0.90 to 23.90)
PAR/RIT12 + OMB12 + DAS12		0.41 (0.02 to 6.40)	-0.22 (-1.81 to 0.92)
PAR/RIT12 + OMB12 + DAS12 + RBV12		10.94 (1.93 to 89.46)	4.48 (1.23 to 11.38)
DCV24 + ASU24 + PR24		11.06 (1.74 to 101.70)	4.39 (0.94 to 13.58)
SOF12 + PR12		40.66 (8.18 to 306.90)	18.24 (9.90 to 30.83)
GRZ12 + ELB12 + RBV12		19.67 (3.35 to 172.20)	8.59 (2.49 to 21.33)
GRZ12 + ELB12 (50 mg q.d.)		1.62 (0.02 to 38.64)	0.25 (-1.36 to 7.38)
GRZ18 + ELB18 (50 mg q.d.)		2.08 (0.02 to 40.77)	0.45 (-1.46 to 7.86)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		12.73 (1.28 to 162.10)	5.46 (0.25 to 21.34)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		27.39 (3.83 to 221.70)	11.85 (2.98 to 30.52)
SOF24 + LDV24 + RBV24	SOF12 + LDV12 + RBV12	1.61 (0.65 to 3.97)	3.59 (-2.74 to 13.04)
T12 PR48 q8		5.96 (3.06 to 13.08)	29.77 (17.96 to 44.07)
SIM12 PR24-48 RGT		2.61 (1.09 to 6.50)	9.42 (0.74 to 21.17)
SIM12 PR48		2.10 (0.96 to 4.89)	6.44 (-0.34 to 15.24)
B32 PR36-48 RGT		7.50 (3.68 to 16.82)	38.82 (22.57 to 57.64)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF12 + RBV12		2.23 (0.78 to 6.54)	7.21 (-1.87 to 23.51)
SOF24 + RBV24		1.21 (0.23 to 4.89)	1.21 (-6.30 to 18.59)
PAR/RIT12 + OMB12 + DAS12		0.03 (0.00 to 0.21)	-5.62 (-10.36 to -2.77)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.86 (0.29 to 2.56)	-0.81 (-6.56 to 6.49)
DCV24 + ASU24 + PR24		0.84 (0.26 to 3.04)	-0.92 (-6.59 to 8.70)
SOF12 + PR12		3.17 (1.36 to 7.73)	12.77 (3.16 to 26.02)
GRZ12 + ELB12 + RBV12		1.54 (0.47 to 4.88)	3.14 (-4.37 to 16.42)
GRZ12 + ELB12 (50 mg q.d.)		0.13 (0.00 to 1.47)	-4.76 (-9.77 to 2.29)
GRZ18 + ELB18 (50 mg q.d.)		0.16 (0.00 to 1.65)	-4.58 (-9.91 to 3.03)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.04 (0.15 to 4.35)	0.20 (-7.09 to 15.96)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		2.07 (0.54 to 6.98)	6.34 (-3.82 to 25.68)
T12 PR48 q8	SOF24 + LDV24 + RBV24	3.75 (1.66 to 9.69)	26.00 (11.18 to 41.53)
SIM12 PR24-48 RGT		1.62 (0.63 to 4.50)	5.74 (-6.11 to 18.56)
SIM12 PR48		1.31 (0.54 to 3.65)	2.86 (-8.04 to 13.28)
B32 PR36-48 RGT		4.66 (2.06 to 11.87)	35.07 (16.86 to 54.76)
SOF12 + RBV12		1.38 (0.46 to 4.59)	3.56 (-8.43 to 20.50)
SOF24 + RBV24		0.75 (0.13 to 3.50)	-2.27 (-13.76 to 15.82)
PAR/RIT12 + OMB12 + DAS12		0.02 (0.00 to 0.17)	-9.27 (-18.97 to -3.71)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.53 (0.17 to 1.83)	-4.38 (-14.60 to 4.23)
DCV24 + ASU24 + PR24		0.52 (0.15 to 2.16)	-4.40 (-14.83 to 6.59)
SOF12 + PR12		1.98 (0.78 to 5.32)	9.19 (-3.59 to 22.84)
GRZ12 + ELB12 + RBV12		0.96 (0.28 to 3.19)	-0.39 (-11.95 to 13.16)
GRZ12 + ELB12 (50 mg q.d.)		0.08 (0.00 to 0.95)	-8.27 (-18.19 to -0.34)
GRZ18 + ELB18 (50 mg q.d.)		0.10 (0.00 to 1.08)	-8.15 (-17.95 to 0.59)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.63 (0.09 to 3.02)	-3.37 (-14.51 to 13.50)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.29 (0.32 to 4.62)	2.70 (-10.43 to 22.38)
SIM12 PR24-48 RGT	T12 PR48 q8	0.43 (0.21 to 0.85)	-20.14 (-36.48 to -4.08)
SIM12 PR48		0.35 (0.23 to 0.53)	-23.14 (-34.47 to -13.76)
B32 PR36-48 RGT		1.26 (0.73 to 2.11)	9.11 (-12.25 to 30.52)
SOF12 + RBV12		0.37 (0.15 to 0.85)	-22.10 (-37.95 to -4.53)
SOF24 + RBV24		0.20 (0.04 to 0.72)	-27.94 (-43.83 to -8.38)
PAR/RIT12 + OMB12 + DAS12		0.00 (0.00 to 0.04)	-35.59 (-49.62 to -24.17)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.14 (0.07 to 0.28)	-30.47 (-41.89 to -20.57)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
DCV24 + ASU24 + PR24		0.14 (0.05 to 0.38)	-30.28 (-43.57 to -18.28)
SOF12 + PR12		0.52 (0.27 to 1.03)	-16.99 (-33.73 to 0.84)
GRZ12 + ELB12 + RBV12		0.26 (0.08 to 0.66)	-26.17 (-42.44 to -9.66)
GRZ12 + ELB12 (50 mg q.d.)		0.02 (0.00 to 0.22)	-34.41 (-48.78 to -21.84)
GRZ18 + ELB18 (50 mg q.d.)		0.03 (0.00 to 0.24)	-34.20 (-48.80 to -21.73)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.17 (0.02 to 0.66)	-29.03 (-44.86 to -10.30)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.35 (0.10 to 0.95)	-22.93 (-40.20 to -1.39)
SIM12 PR48	SIM12 PR24-48 RGT	0.81 (0.36 to 1.86)	-2.92 (-15.70 to 8.21)
B32 PR36-48 RGT		2.89 (1.40 to 6.11)	29.26 (9.36 to 49.67)
SOF12 + RBV12		0.85 (0.30 to 2.41)	-2.21 (-16.29 to 15.64)
SOF24 + RBV24		0.46 (0.09 to 1.90)	-7.99 (-21.14 to 10.39)
PAR/RIT12 + OMB12 + DAS12		0.01 (0.00 to 0.10)	-15.15 (-26.65 to -7.87)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.33 (0.11 to 0.94)	-10.15 (-22.21 to -0.55)
DCV24 + ASU24 + PR24		0.32 (0.10 to 1.12)	-10.12 (-22.13 to 1.31)
SOF12 + PR12		1.22 (0.54 to 2.79)	3.33 (-10.94 to 18.02)
GRZ12 + ELB12 + RBV12		0.60 (0.18 to 1.73)	-6.10 (-19.26 to 8.04)
GRZ12 + ELB12 (50 mg q.d.)		0.05 (0.00 to 0.55)	-14.03 (-25.63 to -4.91)
GRZ18 + ELB18 (50 mg q.d.)		0.06 (0.00 to 0.61)	-13.95 (-25.69 to -4.39)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.39 (0.05 to 1.70)	-9.09 (-22.04 to 8.06)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.80 (0.21 to 2.55)	-3.09 (-17.52 to 17.27)
B32 PR36-48 RGT	SIM12 PR48	3.60 (1.86 to 6.66)	32.34 (14.83 to 50.73)
SOF12 + RBV12		1.07 (0.42 to 2.54)	0.81 (-9.68 to 16.07)
SOF24 + RBV24		0.58 (0.11 to 2.18)	-5.07 (-15.46 to 12.56)
PAR/RIT12 + OMB12 + DAS12		0.01 (0.00 to 0.11)	-12.13 (-20.69 to -6.91)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.41 (0.17 to 0.93)	-7.20 (-14.63 to -0.71)
DCV24 + ASU24 + PR24		0.40 (0.17 to 1.01)	-7.12 (-13.88 to 0.07)
SOF12 + PR12		1.51 (0.68 to 3.40)	6.20 (-5.83 to 20.51)
GRZ12 + ELB12 + RBV12		0.74 (0.22 to 2.04)	-3.14 (-14.09 to 10.22)
GRZ12 + ELB12 (50 mg q.d.)		0.06 (0.00 to 0.68)	-11.09 (-19.97 to -3.25)
GRZ18 + ELB18 (50 mg q.d.)		0.08 (0.00 to 0.68)	-10.94 (-19.84 to -3.30)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.49 (0.07 to 2.02)	-6.10 (-16.31 to 10.25)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.99 (0.27 to 2.93)	-0.08 (-12.55 to 19.37)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF12 + RBV12	B32 PR36-48 RGT	0.30 (0.15 to 0.56)	-30.97 (-45.31 to -17.51)
SOF24 + RBV24		0.16 (0.04 to 0.48)	-36.52 (-52.61 to -21.53)
PAR/RIT12 + OMB12 + DAS12		0.00 (0.00 to 0.03)	-44.74 (-63.08 to -28.79)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.11 (0.04 to 0.30)	-39.51 (-58.12 to -22.41)
DCV24 + ASU24 + PR24		0.11 (0.04 to 0.33)	-39.38 (-58.06 to -22.19)
SOF12 + PR12		0.42 (0.21 to 0.83)	-25.68 (-47.13 to -5.81)
GRZ12 + ELB12 + RBV12		0.20 (0.07 to 0.56)	-35.52 (-55.05 to -15.30)
GRZ12 + ELB12 (50 mg q.d.)		0.02 (0.00 to 0.18)	-43.42 (-62.19 to -26.89)
GRZ18 + ELB18 (50 mg q.d.)		0.02 (0.00 to 0.19)	-43.32 (-62.03 to -26.43)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.13 (0.02 to 0.54)	-38.20 (-57.61 to -16.05)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.28 (0.08 to 0.77)	-32.00 (-52.95 to -8.07)
SOF24 + RBV24	SOF12 + RBV12	0.54 (0.11 to 1.93)	-5.67 (-20.36 to 9.54)
PAR/RIT12 + OMB12 + DAS12		0.01 (0.00 to 0.13)	-13.01 (-28.97 to -5.32)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.38 (0.12 to 1.25)	-8.05 (-23.66 to 1.80)
DCV24 + ASU24 + PR24		0.38 (0.11 to 1.32)	-7.94 (-23.45 to 2.63)
SOF12 + PR12		1.43 (0.51 to 3.92)	5.55 (-13.18 to 20.49)
GRZ12 + ELB12 + RBV12		0.68 (0.19 to 2.37)	-4.04 (-20.49 to 10.65)
GRZ12 + ELB12 (50 mg q.d.)		0.06 (0.00 to 0.71)	-11.85 (-27.91 to -2.51)
GRZ18 + ELB18 (50 mg q.d.)		0.07 (0.00 to 0.75)	-11.74 (-27.78 to -2.12)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.45 (0.06 to 2.33)	-6.81 (-23.29 to 10.82)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.92 (0.22 to 3.34)	-1.06 (-18.61 to 19.07)
PAR/RIT12 + OMB12 + DAS12	SOF24 + RBV24	0.03 (0.00 to 0.34)	-6.85 (-24.50 to -1.09)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.71 (0.16 to 4.07)	-1.94 (-19.06 to 6.66)
DCV24 + ASU24 + PR24		0.71 (0.14 to 4.53)	-1.97 (-19.09 to 8.27)
SOF12 + PR12		2.62 (0.64 to 13.77)	11.20 (-7.94 to 25.38)
GRZ12 + ELB12 + RBV12		1.28 (0.24 to 7.63)	1.89 (-16.48 to 16.16)
GRZ12 + ELB12 (50 mg q.d.)		0.11 (0.00 to 1.92)	-5.68 (-23.53 to 2.79)
GRZ18 + ELB18 (50 mg q.d.)		0.12 (0.00 to 2.13)	-5.74 (-23.44 to 3.09)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.83 (0.09 to 6.74)	-1.13 (-18.72 to 15.91)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.73 (0.31 to 11.13)	4.79 (-13.96 to 24.58)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
PAR/RIT12 + OMB12 + DAS12 + RBV12	PAR/RIT12 + OMB12 + DAS12	28.61 (3.12 to 431.20)	4.77 (1.63 to 11.61)
DCV24 + ASU24 + PR24		29.23 (2.70 to 446.20)	4.68 (1.31 to 13.88)
SOF12 + PR12		106.10 (12.97 to 1,420.00)	18.54 (10.31 to 31.07)
GRZ12 + ELB12 + RBV12		52.34 (4.69 to 845.00)	8.88 (2.78 to 21.53)
GRZ12 + ELB12 (50 mg q.d.)		4.39 (0.03 to 182.70)	0.54 (-0.90 to 7.63)
GRZ18 + ELB18 (50 mg q.d.)		4.57 (0.06 to 181.30)	0.62 (-0.73 to 8.11)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		33.54 (2.34 to 645.10)	5.82 (0.61 to 21.55)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		67.82 (5.84 to 1,253.00)	12.17 (3.31 to 30.84)
DCV24 + ASU24 + PR24	PAR/RIT12 + OMB12 + DAS12 + RBV12	1.00 (0.29 to 3.40)	-0.02 (-6.76 to 8.59)
SOF12 + PR12		3.71 (1.30 to 10.65)	13.53 (2.89 to 26.66)
GRZ12 + ELB12 + RBV12		1.81 (0.45 to 6.57)	3.99 (-5.01 to 17.05)
GRZ12 + ELB12 (50 mg q.d.)		0.16 (0.00 to 1.89)	-3.88 (-10.78 to 3.12)
GRZ18 + ELB18 (50 mg q.d.)		0.18 (0.00 to 1.87)	-3.71 (-10.70 to 3.36)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.20 (0.15 to 5.88)	0.97 (-7.33 to 16.83)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		2.46 (0.56 to 8.84)	7.14 (-3.93 to 26.01)
SOF12 + PR12	DCV24 + ASU24 + PR24	3.76 (1.14 to 12.25)	13.41 (1.56 to 26.77)
GRZ12 + ELB12 + RBV12		1.85 (0.39 to 7.18)	4.02 (-7.12 to 16.94)
GRZ12 + ELB12 (50 mg q.d.)		0.16 (0.00 to 1.96)	-3.77 (-13.13 to 3.19)
GRZ18 + ELB18 (50 mg q.d.)		0.19 (0.00 to 1.93)	-3.60 (-12.93 to 3.33)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.20 (0.15 to 6.42)	0.97 (-9.23 to 16.88)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		2.45 (0.51 to 10.28)	7.03 (-5.14 to 26.31)
GRZ12 + ELB12 + RBV12	SOF12 + PR12	0.49 (0.15 to 1.48)	-9.53 (-23.79 to 6.28)
GRZ12 + ELB12 (50 mg q.d.)		0.04 (0.00 to 0.45)	-17.36 (-30.14 to -7.33)
GRZ18 + ELB18 (50 mg q.d.)		0.05 (0.00 to 0.49)	-17.32 (-30.19 to -6.85)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.32 (0.05 to 1.38)	-12.41 (-26.67 to 5.45)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.66 (0.17 to 2.02)	-6.19 (-22.18 to 14.17)
GRZ12 + ELB12 (50 mg q.d.)	GRZ12 + ELB12 + RBV12	0.08 (0.00 to 1.09)	-7.80 (-20.67 to 0.46)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
GRZ18 + ELB18 (50 mg q.d.)		0.10 (0.00 to 1.18)	-7.69 (-20.54 to 0.94)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.66 (0.09 to 3.55)	-2.85 (-16.73 to 13.60)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.36 (0.31 to 5.49)	3.15 (-11.95 to 22.57)
GRZ18 + ELB18 (50 mg q.d.)	GRZ12 + ELB12 (50 mg q.d.)	1.06 (0.01 to 170.60)	0.02 (-6.27 to 7.12)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		7.68 (0.43 to 725.30)	4.69 (-2.35 to 20.31)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		15.09 (1.32 to 1138.00)	10.95 (1.36 to 29.56)
GRZ12 + ELB12 (50 mg q.d.) + RBV12	GRZ18 + ELB18 (50 mg q.d.)	6.90 (0.45 to 376.00)	4.58 (-2.74 to 19.88)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		13.38 (1.17 to 824.50)	10.87 (1.00 to 29.41)
GRZ18 + ELB18 (50 mg q.d.) + RBV18	GRZ12 + ELB12 (50 mg q.d.) + RBV12	2.07 (0.41 to 14.06)	6.04 (-9.66 to 23.69)
Random effect model	Residual deviance	43.4 vs. 45 data points	
	Deviance information criteria	255.187	
Fixed effect model	Residual deviance	43.87 vs. 45 data points	
	Deviance information criteria	254.562	

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; Crl = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; q12 = every 12 hours; q.d. = once daily; PR = pegylated interferon plus ribavirin; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; T = telaprevir; vs. = versus. Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.